| Year |
Citation |
Score |
| 2018 |
Mostaghel EA, Zhang A, Hernandez S, Marck B, Zhang X, Tamae D, Biehl H, Tretiakova MS, Bartlett J, Burns JF, Dumpit RF, Ang LS, Matsumoto AM, Penning TM, Balk SP, et al. Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30181386 DOI: 10.1158/1078-0432.Ccr-18-1431 |
0.509 |
|
| 2018 |
Jandial R, Neman J, Lim PP, Tamae D, Kowolik CM, Wuenschell GE, Shuck SC, Ciminera AK, De Jesus LR, Ouyang C, Chen MY, Termini J. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. International Journal of Molecular Sciences. 19. PMID 29385725 DOI: 10.3390/Ijms19020406 |
0.626 |
|
| 2017 |
Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley GJ, Montgomery RB, Balk S, Mostaghel E, Blair IA, Penning T. Testicular versus adrenal sources of hydroxyandrogens in prostate cancer. Endocrine-Related Cancer. PMID 28663228 DOI: 10.1530/Erc-17-0107 |
0.495 |
|
| 2017 |
Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck B, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, et al. Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28389510 DOI: 10.1158/1078-0432.Ccr-16-2245 |
0.414 |
|
| 2017 |
Jaramillo R, Shuck SC, Chan YS, Liu X, Bates SE, Lim PP, Tamae D, Lacoste S, O'Connor TR, Termini JS. DNA advanced glycation end products (DNA-AGEs) are elevated in urine and tissue in an animal model of type 2 diabetes. Chemical Research in Toxicology. PMID 28107623 DOI: 10.1021/Acs.Chemrestox.6B00414 |
0.604 |
|
| 2016 |
Zang T, Tamae D, Mesaros C, Wang Q, Huang M, Blair IA, Penning TM. Simultaneous Quantitation of Nine Hydroxy-Androgens and Their Conjugates in Human Serum by Stable Isotope Dilution Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry. The Journal of Steroid Biochemistry and Molecular Biology. PMID 27531846 DOI: 10.1016/J.Jsbmb.2016.08.001 |
0.491 |
|
| 2016 |
Adeniji AO, Uddin MJ, Zang T, Tamae D, Wangtrakuldee P, Marnett LJ, Penning TM. Discovery of (R)-2-(6-methoxynaphthalen-2-yl)butanoic acid As a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. Journal of Medicinal Chemistry. PMID 27486833 DOI: 10.1021/Acs.Jmedchem.6B00160 |
0.639 |
|
| 2016 |
Penning TM, Tamae D. Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer. Current Opinion in Endocrinology, Diabetes, and Obesity. 23: 264-70. PMID 27119752 DOI: 10.1097/Med.0000000000000253 |
0.53 |
|
| 2015 |
Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TM. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chemico-Biological Interactions. 234: 332-8. PMID 25514466 DOI: 10.1016/J.Cbi.2014.12.012 |
0.556 |
|
| 2015 |
Mostaghel EA, Cho E, Wright JL, Loda M, Marck B, Matsumoto AM, Tamae D, Penning TM, Balk SP, Kantoff PW, Nelson P, Taplin M, Montgomery RB. Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa). Journal of Clinical Oncology. 33: 5013-5013. DOI: 10.1200/Jco.2015.33.15_Suppl.5013 |
0.457 |
|
| 2015 |
Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin M, Penning TM. Abstract 3450: Resistance to P450c17 inhibitors in castration-resistant prostate cancer may result from the DHEA-S depot that remains and can be used by AKR1C3 for intratumoral androgen biosynthesis Cancer Research. 75: 3450-3450. DOI: 10.1158/1538-7445.Am2015-3450 |
0.577 |
|
| 2014 |
Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, ... ... Tamae D, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3705-15. PMID 25311217 DOI: 10.1200/Jco.2013.53.4578 |
0.498 |
|
| 2014 |
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, et al. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 229-37. PMID 24323034 DOI: 10.1200/Jco.2012.48.6431 |
0.526 |
|
| 2014 |
Mostaghel EA, Marck B, Matsumoto AM, Tamae D, Penning TM, Balk SP, Kantoff PW, Nelson P, Taplin M, Montgomery RB. Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa). Journal of Clinical Oncology. 32: 5015-5015. DOI: 10.1200/Jco.2014.32.15_Suppl.5015 |
0.524 |
|
| 2014 |
Wang T, Diaz AJ, Li J, Yen Y, Tamae D. Abstract 3953: Enhanced radiation reponse in MCF-7 radioresistant cells by targeting Peroxiredoxin II Cancer Research. 74: 3953-3953. DOI: 10.1158/1538-7445.Am2014-3953 |
0.319 |
|
| 2013 |
Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W, True L, Vessella R, Montgomery B, Blair IA, Penning TM. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. The Journal of Steroid Biochemistry and Molecular Biology. 138: 281-9. PMID 23851165 DOI: 10.1016/J.Jsbmb.2013.06.014 |
0.525 |
|
| 2013 |
Richie JP, Montgomery RB, Logothetis CJ, Bubley GJ, Dalkin BL, Sanda MG, Loda MF, Lis RT, True LD, Troncoso P, Genega EM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, ... ... Tamae D, et al. 665 EFFECT OF NEOADJUVANT ABIRATERONE ACETATE PLUS LEUPROLIDE ACETATE ON PSA, PATHOLOGIC RESPONSE, AND INTRAPROSTATIC/SERUM ANDROGEN LEVELS IN LOCALIZED HIGH-RISK PROSTATE CANCER: RESULTS OF A RANDOMIZED PHASE 2 STUDY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.220 |
0.458 |
|
| 2011 |
Tamae D, Lim P, Wuenschell GE, Termini J. Mutagenesis and repair induced by the DNA advanced glycation end product N 2-1-(carboxyethyl)-2′-deoxyguanosine in human cells Biochemistry. 50: 2321-2329. PMID 21355561 DOI: 10.1021/Bi101933P |
0.62 |
|
| 2010 |
Wuenschell GE, Tamae D, Cercillieux A, Yamanaka R, Yu C, Termini J. Mutagenic potential of DNA glycation: Miscoding by (R)- and (S)-N 2-(1-carboxyethyl)2′-deoxyguanosine Biochemistry. 49: 1814-1821. PMID 20143879 DOI: 10.1021/Bi901924B |
0.62 |
|
| 2008 |
Synold T, Xi B, Wuenschell GE, Tamae D, Figarola JL, Rahbar S, Termini J. Advanced glycation end products of DNA: Quantification of N 2-(1-carboxyethyl)-2′-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry Chemical Research in Toxicology. 21: 2148-2155. PMID 18808156 DOI: 10.1021/Tx800224Y |
0.63 |
|
| Show low-probability matches. |